Value for money in disease management of acute coronary syndrome--the price of aspirin to reduce the costs of ACS.
Curtiss
Frederic R
FR
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000191:economics* / Q000627:therapeutic use; D001241:Aspirin / Q000191:economics* / Q000627:therapeutic use; D000069059:Atorvastatin; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000188:drug therapy / Q000517:prevention & control*; D006538:Heptanoic Acids / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use; D017035:Pravastatin / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use; D011758:Pyrroles / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use
D000894:Anti-Inflammatory Agents, Non-Steroidal; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011758:Pyrroles; D000069059:Atorvastatin; D017035:Pravastatin; D001241:Aspirin